Technical Analysis for POAI - Predictive Oncology Inc.

Grade Last Price % Change Price Change
grade C 3.9 -9.30% -0.40
POAI closed down 9.3 percent on Monday, November 11, 2019, on 39 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Very Strong Up Up Down
See historical POAI trend table...

Date Alert Name Type % Chg
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Down 3 Days in a Row Weakness 0.00%
Calm After Storm Range Contraction -9.30%
Inside Day Range Contraction -9.30%
Wide Bands Range Expansion -9.30%
Overbought Stochastic Strength -9.30%
Slingshot Bullish Bullish Swing Setup -11.56%

Older signals for POAI ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Predictive Oncology (formerly Precision Therapeutics Inc.) (Nasdaq: AIPT until June 12, 2019; POAI starting June 13, 2019) operates through its three business units, Helomics, TumorGenesis and Skyline Medical. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™, patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform (D-CHIP) to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners.
Medicine Biotechnology Cancer Pharmaceutical Clinical Medicine Oncology Artificial Intelligence Ovarian Cancer Cell Biology Genomics Tumors FDA Cancer Therapies Targeted Therapy Biomarkers Bioinformatics Proteomics Precision Medicine
Is POAI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.39
52 Week Low 0.35
Average Volume 71,001
200-Day Moving Average 0.8501
50-Day Moving Average 1.2264
20-Day Moving Average 2.3127
10-Day Moving Average 4.1963
Average True Range 0.4709
ADX 62.88
+DI 47.2217
-DI 12.7531
Chandelier Exit (Long, 3 ATRs ) 3.9773
Chandelier Exit (Short, 3 ATRs ) 1.7627
Upper Bollinger Band 6.1073
Lower Bollinger Band -1.4819
Percent B (%b) 0.71
BandWidth 328.153241
MACD Line 1.0399
MACD Signal Line 0.8532
MACD Histogram 0.1867
Fundamentals Value
Market Cap 24.3 Million
Num Shares 6.23 Million
EPS -1.11
Price-to-Earnings (P/E) Ratio -3.51
Price-to-Sales 21.74
Price-to-Book 3.75
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.95
Resistance 3 (R3) 5.03 4.77 4.78
Resistance 2 (R2) 4.77 4.50 4.73 4.72
Resistance 1 (R1) 4.33 4.33 4.20 4.25 4.66
Pivot Point 4.07 4.07 4.00 4.03 4.07
Support 1 (S1) 3.63 3.80 3.50 3.55 3.14
Support 2 (S2) 3.37 3.63 3.33 3.08
Support 3 (S3) 2.93 3.37 3.03
Support 4 (S4) 2.85